The mechanics of a prescribing cascade are deceptively simple, which is precisely what makes them so difficult to catch in busy clinical practice. Consider one of the clearest examples highlighted in the study: non-steroidal anti-inflammatory drugs, or NSAIDs, which are among the most widely used medications for pain relief in older populations. NSAIDs are known to raise blood pressure in many patients. When that rise occurs, it can easily be read as the emergence of hypertension, a genuine and serious condition in its own right, leading to a new prescription for antihypertensive medication. What gets lost in that transaction is the causal thread connecting the two drugs. The patient now takes two medications instead of one, carries the side-effect burden of both, and the underlying trigger, the NSAID itself, remains untouched. The cascade, once established, can continue to grow.

Older adults are especially vulnerable to this pattern for reasons that are both biological and structural. Advanced age typically brings multiple chronic conditions, and multiple conditions mean multiple prescribing physicians, multiple pharmacies and, frequently, a long list of concurrent medications. When a new symptom appears in a patient taking ten or twelve drugs, tracing it back to a specific medication started months earlier is a formidable task for even the most diligent clinician. The symptom is more likely to be attributed to aging, to one of the existing diagnoses, or to a genuinely new disease. Dr. Rochon, who holds the Barry J. Goldlist Chair in Aging and Health at Sinai Health and is a professor of medicine at the University of Toronto, emphasized that these sequences of events are common but often missed in clinical practice. Knowing what medications a patient is taking, when each one was started, and for what indication, she noted, is essential for identifying problematic cascades before they compound.

To move the problem from anecdote to evidence, the research team assembled an interdisciplinary, international group of collaborators and leaders in drug prescribing and geriatric medicine research spanning the United States, Belgium, Italy, Israel and Ireland. The Canadian side of the effort included Sinai Health researchers Drs. Vasily Giannakeas, Nathan Stall and Christina Reppas-Rindlisbacher, along with research staff Wei Wu and Joyce Li. Working with Lavina Matai and Zhiyin Li at ICES, Ontario’s health data institute, the team gained access to population-level prescription data covering the province, an unusually powerful foundation for studying how prescribing patterns unfold across millions of patients over time rather than within the confines of a single clinic or hospital.

The analytical framework rested on work the team had completed previously: with the expertise of twelve international panelists specializing in internal medicine, geriatric medicine and clinical pharmacology, the researchers had compiled a list of sixty-five potentially inappropriate prescribing cascades drawn from the medical literature and expert consensus. Each cascade on that list describes a first drug, a second drug prescribed in response to the first drug’s adverse effect, and a plausible biological mechanism linking the two. The Ontario study then subjected all sixty-five candidates to a rigorous population-level test built on three criteria. First, how common was the initial drug in the population? Second, how often was it actually followed by the second drug in real-world prescribing data? Third, how strong was the observed link between the two prescriptions?

That three-part analysis allowed the researchers to distill the field down to the twenty-four potentially inappropriate prescribing cascades that are both most commonly seen in the Ontario population and most likely to cause harm. The list spans a striking range of everyday therapeutics. Beyond the NSAID-to-blood-pressure-medication pathway, the study points to cascades involving statins, iron supplements and other widely dispensed drugs, illustrating that the risk is not confined to exotic or high-alert medications. It is embedded in the routine, well-intentioned prescribing that happens thousands of times a day across the province. Because the analysis was conducted at the level of an entire population rather than a selected cohort, the findings offer some of the strongest evidence yet that prescribing cascades are a systemic issue rather than a collection of individual clinical errors.

For Dr. Rochon, the findings illuminate a gap that opens quietly, one prescription at a time. Her concern, she explained, is that the conversations between prescribers and patients that would reveal these connections are so often missed, leaving both parties unaware that a sequence of events is unfolding and that the events are connected to one another. Closing that gap, the team argues, requires physicians to treat medication history as a living document that deserves attention at every visit, not merely a static list of current drugs. Clinicians need to ask why each medication was started in the first place, when it was initiated, and whether the newest prescription on the list is genuinely treating a new disease or simply patching over the side effect of an older one. That reflective pause, applied consistently, could interrupt a cascade before a second or third drug is ever added.

The findings carry particular weight for mature women, a population that sits at the center of Dr. Rochon’s research program. Women tend to live with more chronic conditions than men over their lifetimes, are prescribed more drug therapies, and experience more adverse drug events. Each additional medication increases the surface area for harm, and each additional condition complicates the diagnostic picture when a new symptom emerges. A woman managing osteoporosis, arthritis, cardiovascular risk factors and other conditions simultaneously faces a heightened probability that a drug’s side effect will be mistaken for a new diagnosis rather than traced back to its source. The study’s population-level lens makes clear that this is not a marginal concern but a structural feature of how care is delivered to older women, and one that deserves targeted attention in prescribing guidelines and clinical education alike.

The research team’s conclusions point toward concrete, technologically feasible next steps. The first involves automated clinical decision support tools embedded directly in electronic prescribing systems. Such tools could flag a potential prescribing cascade in real time, alerting the prescriber at the exact moment a new prescription is about to be added that the patient is already taking a drug known to produce the symptom now being treated. Delivered at the point of care, this kind of automated awareness could transform prescribing cascades from an invisible population-level phenomenon into a visible, actionable warning. The technology required is not speculative; the underlying data linkages and rule-based logic mirror systems already used to flag drug allergies and dangerous interactions.

The second proposed step is organizational rather than technical: optimizing the role of pharmacists as full members of the care team and integrating them more directly into the prescribing process alongside physicians. Pharmacists possess precisely the expertise needed to spot the signature of a prescribing cascade, a new drug whose start date closely follows an older drug with a known adverse-effect profile, and to initiate a medication review before the cascade deepens. Together, the two strategies address the problem from complementary angles, embedding vigilance in both the software that supports prescribing decisions and the professional relationships that surround them. As populations age and polypharmacy becomes the norm rather than the exception, the Ontario study suggests that the question is no longer whether prescribing cascades cause widespread harm, but how quickly health systems can build the safeguards needed to stop them.

Subject of Research: Potentially inappropriate prescribing cascades in older adults identified through population-level analysis of Ontario prescription data

Article Title: Ontario study identifies potentially harmful drug combinations prescribed to older adults

Article References: Ontario study identifies potentially harmful drug combinations prescribed to older adults. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: prescribing cascades, older adults, polypharmacy, medication safety, geriatric medicine, NSAIDs, blood pressure, statins, clinical decision support, pharmacists, mature women's health, The BMJ